Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Testimonials
Our products and services certainly speak for themselves, however sometimes, testimonials from our customers can go a long way. Below are just a few of our recent satisfied customers.
Dr. Jennifer Connelly, MD, Associate Professor of Neurology
Froedtert Health and Medical College of Wisconsin
Take a look at the MRIs from yesterday compared to the prior one. The T1 with contrast is hard to interpret but I think the [standardized] Delta T1 says it all.
Jamie Beaudry, Director of Imaging Services
Froedtert and the Medical College of Wisconsin
We've been working with Imaging Biometrics for more than a year and have found the organization to be extremely organized and responsive. They are very collaborative in working with the leadership and staff who've been involved with our MR-focused initiative to improve patient scheduling and reception and to stream-line processes to improve patient satisfaction and department efficiency.
They've definitely put in the time and effort to get to know our department, staff, and workflows to better understand the challenges we face. I appreciate how they continuously check in to make sure we are moving in the right direction and getting the outcomes we expect.
Froedtert & the Medical College of Wisconsin has used LEAN principles for many years for numerous process improvement initiatives across our hospital and health system. We are pleased that Imaging Biometrics is supporting us in this specific endeavor in our Imaging Services department.
Froedtert & the Medical College of Wisconsin Hospital is a 500-bed academic medical center and a leading referral resource for advanced medical care. Froedtert Hospital also operates the region's only adult Level 1 Trauma Center. The primary adult teaching affiliate of the Medical College of Wisconsin, Froedtert Hospital is a major training facility for more than 1,000 medical, nursing, and health technical students annually. It is also a respected research center, participating in some 2,000 research studies, including clinical trials, every year. Froedtert Hospital is located on the Milwaukee Regional Medical Center campus. Campus partners are: BloodCenter of Wisconsin, Children's Hospital of Wisconsin, Curative Care Network, the Medical College of Wisconsin, and the Milwaukee County Behavioral Health Division. For more information, visit froedtert.com.
An interactive virtual reality solution, EchoPixel uses existing DICOM image data to allow clinicians to create and interact with life-size holographic objects of patient anatomy for diagnostics, surgical planning and interventional radiology.
Investments aim at interoperability, value-based care
Rounding out our activity, two strategic buyers -- Konica Minolta through its acquisition of Invicro and ERT Clinical with its acquisition of Cleveland Clinic's Biomedical Imaging and Analysis Center -- acquired clinical trial imaging capabilities. These acquisitions offer a clear reminder of the increasing importance of imaging in drug discovery.
In addition, LifeImage, a medical information network connecting other healthcare networks, providers and patients to imaging records, raised an additional $6.5 million last April; the growing emphasis on industry interoperability makes this transaction stand out. Value-based healthcare marches on, if at a slower-than-hoped-for pace, and Philips' acquisition of Analytics Informatics and its performance improvement solution in November 2017 highlights the continued emphasis on quality and performance.
AI was the star of the medical imaging market in my research, with workflow and post-processing remaining key overarching topics. There was some highlighting of innovative technologies and a reminder about the importance of imaging for clinical trials, along with brief cues about interoperability and the need for quality and performance. All in all, a year of robust transactions in the medical imaging market.
They have various foci and levels of capability in single versus multiple clinical areas, single versus multimodality and differing emphasis on radiologist workflow. For example, Ultromics focuses on improving cardiovascular disease diagnostics specifically using echocardiograms, while Zebra Medical's capabilities include liver, lung, cardiovascular and bone disease. In addition to its diagnostic capabilities, AIDoc Medical provides radiologist workflow enhancement by previewing the clinical data for the radiologist that's most relevant for interpretation.
All that said, we likely have a few more years before AI-enhanced imaging tools become mainstream. KLAS Research published a report in February 2018 called "Artificial Intelligence in Imaging 2018: Early Adopters Speak Out." In the report, KLAS spoke with 81 healthcare organizations -- primarily large, integrated delivery networks -- about each organization's early use of and plans for AI in imaging. Perhaps not surprising to many industry observers, 53% of respondents had no current plans to use AI in imaging, and only 17% of respondents were live or piloting AI. Of the 30% of respondents that were planning to use AI, only 21% expected to go live in less than a year, while 41% had go-live plans for the next year or two and 15% expected adoption to take five-plus years.
Emerging technologies
Venture investors interested in diagnostic imaging typically look for emerging technologies, and while they accounted for only 12% of the medical imaging market transactions, the three emerging tech companies funded within the period I researched all use imaging technologies in new and creative ways:
Analytics 4 Life wants to enhance cardiac imaging and the assessment of coronary artery diseases. The company takes intrinsic signals emitted by the heart and, with AI, measures and mathematically models those signals using phase space tomography -- a field of math and physics that models dynamic systems and allows the company's imaging process to be completed without radiation, contrast agents or cardiac stress.
Ortho Kinematics created a new diagnostic tool for the assessment of spinal instability and alignment, which was historically measured by hand from static x-rays. The tool, called Vertebral Motion Analysis (VMA), uses fluoroscopic imaging during controlled patient movement -- while VMA devices assist patients through the motion of a spine bend -- combined with additional image processing and motion analysis. With this new technology, Ortho Kinematics claims the ability to increase sensitivity in detecting lumbar radiographic instability by 500%.
An interactive virtual reality solution, EchoPixel uses existing DICOM image data to allow clinicians to create and interact with life-size holographic objects of patient anatomy for diagnostics, surgical planning and interventional radiology.
Investments aim at interoperability, value-based care
Rounding out our activity, two stra
Investors in medical imaging technology leaned toward software that improves AI-related radiology and associated workflows, as evidenced by detailed research. o find out the types of diagnostic imaging software that companies have been gaining favor with and see what medical imaging market trends the data revealed, I investigated strategic acquisitions in medical imaging as well as areas attracting investments.
With nine acquisitions and close to a quarter-billion dollars in investments, the 16 months from March 2017 through June 2018 were busy for the medical imaging space. My research also revealed the following:
AI-enabled medical image analysis emerged as the big winner, with nine companies raising a combined $130 million in investments.
With $52 million spread among three investments, other emerging technologies were silver medalists.
Next up was a single $16-million investment and two additional acquisitions in image post-processing without the use of AI as well as a single $30-million investment in workflow tools -- a category that also saw two acquisitions.
Imaging for clinical trials was also noteworthy, with two vendors acquired by strategic buyers.
Finally, there were companies that don't necessarily fit into any of the above categories: Two investments received a combined $13 million in funding, and three other companies were acquired.
Improved radiologist workflow capabilities
During the 16-month period I researched, investments and acquisitions in the imaging space overwhelmingly focused on improving post-processing and workflow for radiologists using traditional and AI-enabled methods; 15 of the 25 transactions fall into this category. Simply, this trend speaks to improving radiologist diagnostic capability and speed with enhanced and, in some cases, intelligent post-processing capabilities and workflow. Since radiologists clearly offer an expensive and limited resource, improving their efficacy and efficiency has been a key goal for the last few years -- although for medical imaging market transactions in this category, 60% was higher than I expected.
AI-enabled medical image analysis
Imaging is a key area in which AI has the potential for significant near- to mid-term impact, so I anticipated that investors would seek out related opportunities, which we've obviously seen in this data. The nine companies that received investments -- AIDoc Medical, Zebra Medical Vision, Ultromics, Bay Labs, Imagen, VoxelCloud, Brainomix, Huiyi Hui Ying and 12 Sigma Technologies -- have all embraced AI to assist in identifying abnormalities and assorted other clinical findings in medical images.
Since radiologists clearly offer an expensive and limited resource, improving their efficacy and efficiency has been a key goal for the last few years.
They have various foci and levels of capability in single versus multiple clinical areas, single versus multimodality and differing emphasis on radiologist wo
actually their holding was diluted by the placing. West Coast Capital Investments 7,559,934 6.28%
In March 2001, Hunter was a founding partner of West Coast Capital, the private equity arm of the Hunter Family. Through this firm, he has become a major shareholder in a number of retailers – including USC, Office, D2, Qube; and 8% of British Home Stores (BHS), with the bulk owned by Sir Philip Green, subsequently disposing of them all. His other investments included Wyevale Garden Centres.[2][4]
At its height, West Coast investments covered over 50 companies, and Hunter was touted as a possible bidder for Selfridges – he lost out to Galen Weston.[8] However, in light of the Financial crisis of 2007–2008 he sold his stake in Dobbies Garden Centres to partner Tesco, lost his entire holding in Crest Nicholson; and a majority of his stakes in McCarthy & Stone and Wyevale Garden Centres.[9]
West Coast Capital now holds a number of major investments in property, ecommerce and data analytics including a large stake in listed Secure Income Reit Plc, majority control of the £1 billion Winchburgh Village development and a substantial stake in Order Dynamics. West Coast Capital directly funds, alongside the Hunter Family, venture philanthropy, The Hunter Foundation.
Wonder if Dr Qu Li and Vinod have got shares yet - they must be in the placing probably.
West Coast invesments owns 10.45% - West Coast is a company of Tom Hunters. Sir Thomas Blane Hunter (born 6 May 1961) is a Scottish businessman,[1] entrepreneur, and philanthropist.
In April 2007, Hunter was reported in the Sunday Times Rich List as the first ever home-grown billionaire in Scotland, with an estimated wealth of £1.05 billion.[2] Due to the financial crisis of 2007–2010 slicing an estimated £250 million from his fortune, Hunter was overtaken as Scotland's richest man in late 2007 by Jim McColl, head of Glasgow engineering firm Clyde Blowers, who has an estimated fortune of £800 million.[3]
Thanks Cash , I'm sitting tight and may even add a few more :) One of my others is coming good Luceco a recovering one , good potential for moving up . A better day , so glad I dumped ukog what a terrible BB many snipes and too volatile . More potential here . Let's have a good finish. Enjoy your weekend , I'm dancing all weekend .
No worries sis. This stuff happens. Investing is ruthless. You need strategies, nerves of steel and guts to make the right decisions. So take yr time in what you do. This is a good board to have sensible discussions. Ask while you can cos I have a feeling things on here will get nasty once the herd arrive. There is so much going on for this share and its mcap is still really low. So it has to go up in its own time. Here it is about getting that fda approval and then patience till the sales start
Thank you Cash and FB for being polite :) That is what happened and being a new investor I was simply trying to understand . When I last dabbled it was teletext days , which actually I found better. Most times after hours trading seems to have had a negative impact on the SP , but it soon bounces back . I got rid of two other holdings , one being Thor I despaired there ! I now have 4 , Flyinh is one I have a good feeling about , and yes generally this board is a nice one , I guess you'll always get the odd rude person that's life . Good luck :)
Rochester, New York, January 17, 2018. aycan, a recognized worldwide leader in medical imaging, in conjunction with business partner Imaging Biometrics, a company specializing in the development of software solutions for advanced visualization and analytics, announced today that Stanford University’s 3D and Quantitative Imaging Laboratory will utilize aycan workstation with Imaging Biometrics software to image brain tumors in patients and assess their response to treatment.
Among the Imaging Biometrics (IB) software the Stanford Lab will run on aycan workstation is IB Rad Tech, which makes the generation of IB’s exclusive and sophisticated image maps, such as FTB (fractional tumor burden), easy and repeatable. Standardized FTB (sFTB) maps include exclusive image-intensity standardization technology, which enables quantitative and rapid longitudinal comparison on magnetic resonance (MR) imaging.
aycan workstation is an FDA 510(k) cleared, vendor-neutral, highly functional advanced image-processing tool and DICOM PACS workstation for conventional, multi-slice and other image reading. IB’s full suite of FDA cleared software is available for aycan workstation, and includes IB Rad Tech, IB Neuro, IB DCE, IB Delta Suite, and IB Diffusion.
Imaging Biometrics lands Stanford installation
By AuntMinnie.com staff writers
January 19, 2018 -- Advanced visualization software developer Imaging Biometrics has landed a deal to install its software at Stanford University's 3D and Quantitative Imaging Laboratory.
The lab will install a variety of the company's applications on its aycan workstation software from radiology informatics firm Aycan Medical Systems for imaging brain tumors and assessing treatment response. Among the applications is the company's IB Rad Tech program, which makes it easy and repeatable to generate image maps such as fractional tumor burden.
Fractional Tumor Burden
A 57 year-old male with a history of brain tumor surgically removed in 1999 and underwent focal radiation therapy. 17 years later, the tumor resurfaced. A magnetic resonance image (MRI) exam of the brain was performed using contrast media that highlights tumor tissue. In addition, perfusion imaging was performed that allows calculation of blood flow in the brain.Recently acquired tools such as IB Rad Tech solution by Imaging Biometrics allow further delineation of the tumor through analysis and measurements of the highlighted sections; because the highlights can also be scar tissue from radiation therapy. Figures A and B demonstrate the separation of tissue elements after the analysis.
Soul sister my apologies if I were rude. Not my intention. Please do post again if you have questions. Unlike other boards this is a friendly one and we share views and ideas. Don’t think anyone was trying to be rude. Good luck with yr investments and do be careful. Only invest what u can afford to lose, do you research properly and learn how to be patient. I lost a money most of the time cos I was impatient but not with fbdu. All the best sister and come back!
though to be fair if you were new and saw delayed trades coming through after hours and all the stuff they put through after the bell you may ask the question
lol, calm down, you sound like Roxanne pallett. all i said was its probably worth reading up on the markets first, certainly wasnt trying to be obnoxious.
There's no need to be rude , I'm trying to learn . Did it warrant that answer, why not try and help new investors instead. Last time I post . Farewell
I will throw my weight behind that comment too draft
soulsister - you need to work on your basic understanding of the market before you go any further i think...
Nope it does not
I thought it traded after hours ?
the market is open from 8am to 4:30pm. After that anything that happens on here price wise is not right so just ignore LSe outside market hours.
Well the share price on here at midnight has gone up by .20 so 8am should See it hit a high . Fingers crossed hope I got that right